Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Steven Keller Added: 1 year ago
Author(s): Added: 9 months ago
TIMELY is an integrated AI-based healthcare solution consisting of a certified physician platform and a patient app. It has been developed within an EU-funded project running from 2021 to 2025. TIMELY aims to assist both cardiac patients and their clinicians in personalising healthcare by evaluating risks and offering individualised exercise recommendations. The solution has been evaluated within… View more
Author(s): Brian Lindman Added: 8 months ago
ACC 2025 - Primary findings from EARLY-TAVR show the benefit of early TAVR intervention was consistent across biomarker subgroups.Dr Brian Lindman (Vanderbilt University Medical Center, Nashville, US) joins us onsite at ACC 2025 to discuss findings from the primary biomarker analysis from the EARLY TAVR trial (NCT03042104; Edwards Lifesciences). The analysis investigated cardiac biomarkers in… View more
Added: 3 months ago Source:  Radcliffe Cardiology
Early withdrawal of aspirin in favour of potent P2Y12 inhibitor monotherapy following percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) did not meet the criteria for noninferiority regarding ischaemic events compared to standard dual antiplatelet therapy (DAPT), according to the results of the NEO-MINDSET trial.¹ The strategy did, however, demonstrate superiority in… View more
Added: 1 month ago Source:  Transcatheter Academy
An individual patient data (IPD) meta-analysis has found that using fractional flow reserve (FFR) to guide percutaneous coronary intervention (PCI) is associated with a significant reduction in major adverse events compared to a standard angiography-guided strategy. The benefit appears to be driven primarily by a reduction in peri-procedural myocardial infarction (MI).¹The PRIME Collaboration… View more